Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Operating Leases: 2022-2024

Historic Operating Leases for Immunocore Holdings (IMCR) over the last 3 years, with Dec 2024 value amounting to $40.2 million.

  • Immunocore Holdings' Operating Leases rose 2.14% to $43.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.3 million, marking a year-over-year increase of 2.14%. This contributed to the annual value of $40.2 million for FY2024, which is 12.78% up from last year.
  • Immunocore Holdings' Operating Leases amounted to $40.2 million in FY2024, which was up 12.78% from $35.6 million recorded in FY2023.
  • Over the past 5 years, Immunocore Holdings' Operating Leases peaked at $40.2 million during FY2024, and registered a low of $31.8 million during FY2022.
  • In the last 3 years, Immunocore Holdings' Operating Leases had a median value of $35.6 million in 2023 and averaged $35.8 million.
  • Data for Immunocore Holdings' Operating Leases shows a peak YoY rose of 12.78% (in 2024) over the last 5 years.
  • Immunocore Holdings' Operating Leases (Yearly) stood at $31.8 million in 2022, then grew by 12.13% to $35.6 million in 2023, then climbed by 12.78% to $40.2 million in 2024.